To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable,Symptomatic Chronic Angina

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 336 participants.

Also called NCT02623569

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 336 participants (planned count) (from the registry)
Sponsor
Xintong Pharmacy Company (from the registry)
Registry
  • NCT NCT02623569
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02623569. Randomized; quadruple masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2017-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable,Symptomatic Chronic Angina
Condition
Angina Pectoris
Intervention (Drug)
Ivabradine
Intervention (Drug)
Atenolol
Lead sponsor
Xintong Pharmacy Company (class: other)

Record details

Record id
cardio:ct-nct02623569
Content hash
c25245183d174f7bc3b18a07add077dab5580c079cc31ff0af59815326eeeb49